AroCell presenterar resultat från U-CAN TK1 lymfomstudien samt från en studie där TK 210™ ELISA jämförs med andra metoder
November 27, 2018 09:00 ET | AroCell AB
I samband med ISOBMs kongress (International Society of Oncology Biomarkers) i Hamburg, presenterar idag AroCell’s forskningschef, Staffan Eriksson, nya preliminära kliniska resultat från U-CAN TK1...
Logo (3).png
Cancer Immunotherapy Market Worth $152.83 Billion by 2024 - Exclusive Report by Meticulous Research®
October 30, 2018 09:18 ET | Meticulous Market Research Pvt. Ltd.
LONDON, Oct. 30, 2018 (GLOBE NEWSWIRE) -- According to the latest publication from Meticulous Research®, the global cancer immunotherapy market is expected to grow at a CAGR of 13.8% from 2018 to...
Patent granted in the US
October 17, 2018 02:30 ET | AroCell AB
AroCell announced today that the U.S. Patent and Trademark Office has granted AroCell´s patent US 10,100,128 titled ”Monoclonal Anti-TK1 Antibodies”. The patent refers to AroCell’s...
Patent godkänt på den amerikanska marknaden
October 17, 2018 02:30 ET | AroCell AB
AroCell meddelar idag att det amerikanska patentverket har godkänt och utfärdat AroCells patent US 10,100,128 ”Monoclonal Anti-TK1 Antibodies”. Patentet avser AroCells monoklonala antikroppar...
Patent reinforces AroCell’s opportunities in the US market
August 29, 2018 09:15 ET | AroCell AB
AroCell AB has received a Notice of Allowance stating that the U.S. Patent and Trademark Office intends to grant the company's patent application no. 15/105,999 titled ”Monoclonal Anti-TK1...
Patent förstärker AroCells möjligheter på den amerikanska marknaden
August 29, 2018 09:15 ET | AroCell AB
Patent förstärker AroCells möjligheter på den amerikanska marknaden AroCell har meddelats att det amerikanska patentverket avser att godkänna bolagets patentansökan nr. 15/105,999 ”Monoclonal...
The-Business-Research-Company-horizontal-logo-2.png
The Business Research Company announces the launch of its report Global Biologics Market Opportunities And Strategies To 2022
August 22, 2018 08:00 ET | The Business Research Company
LONDON, Aug. 22, 2018 (GLOBE NEWSWIRE) -- This exciting report shows that the growth rate in the global biologics drugs market has accelerated recently and is now almost 10% year on year.   By 2022...
Aegis is Awarded US Patent for Formulation and Non-invasive Delivery of Peptide Drugs
August 15, 2018 06:00 ET | Aegis Therapeutics LLC
SAN DIEGO, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded US Patent No. 10,046,025, providing non-invasive delivery of cyclic peptide drugs....
Aegis Expands its International and US Intravail® Patent Portfolio on Multiple Fronts
August 02, 2018 06:00 ET | Aegis Therapeutics LLC
SAN DIEGO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded European Patent No. EP2381773(B1) and Canadian Patent No. 2,748,268, providing fast...
logo long.jpg
Global Recombinant Therapeutic Antibodies and Proteins Market to Surpass US$ 250 Billion by 2026
July 23, 2018 08:00 ET | Coherent Market Insights
SEATTLE, July 23, 2018 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global recombinant therapeutic antibodies and proteins market is estimated to be valued at US$ 91.2 billion in...